OTCMKTS:GNMSF - Genmab A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$161.55 +6.60 (+4.26 %)
(As of 12/12/2018 11:25 AM ET)
Previous Close$154.95
Today's Range$161.10 - $161.55
52-Week Range$119.10 - $213.00
Volume477 shs
Average Volume508 shs
Market Capitalization$9.51 billion
P/E Ratio59.83
Dividend YieldN/A
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; HuMax-TAC-ADC (ADCT-301) to treat lymphoma and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for metastatic solid tumors; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 for MM; and AMG 714 for the treatment of celiac disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio19.94
Quick Ratio19.94


Trailing P/E Ratio59.83
Forward P/E Ratio53.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$359.31 million
Price / Sales27.55
Cash Flow$2.8517 per share
Price / Cash Flow56.65
Book Value$15.57 per share
Price / Book10.38


EPS (Most Recent Fiscal Year)$2.70
Net Income$167.62 million
Net Margins48.74%
Return on Equity19.83%
Return on Assets18.82%


Outstanding Shares61,280,000
Market Cap$9.51 billion
OptionableNot Optionable

Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings data on Wednesday, November, 5th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.45 by $0.02. The firm earned $45.65 million during the quarter, compared to the consensus estimate of $53.94 million. Genmab A/S had a return on equity of 19.83% and a net margin of 48.74%. View Genmab A/S's Earnings History.

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release their next quarterly earnings announcement on Wednesday, December 12th 2018. View Earnings Estimates for Genmab A/S.

What is the consensus analysts' recommendation for Genmab A/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genmab A/S.

Has Genmab A/S been receiving favorable news coverage?

Media stories about GNMSF stock have trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Genmab A/S earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.

Who are some of Genmab A/S's key competitors?

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the folowing people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 57)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 57)
  • Dr. Judith Klimovsky, Exec. VP & Chief Devel. Officer (Age 60)
  • Ms. Jane Juel, Sr. Director of Operations & Resource Management
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting and R&D Operations

How do I buy shares of Genmab A/S?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $161.55.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $9.51 billion and generates $359.31 million in revenue each year. The company earns $167.62 million in net income (profit) each year or $2.70 on an earnings per share basis. Genmab A/S employs 309 workers across the globe.

What is Genmab A/S's official website?

The official website for Genmab A/S is http://www.genmab.com.

How can I contact Genmab A/S?

Genmab A/S's mailing address is BREDGADE 34E, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]

MarketBeat Community Rating for Genmab A/S (OTCMKTS GNMSF)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: What are earnings reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel